Immunomedics Inc. (IMMU) belonging to the Medical sector has declined -1.12% and closed its last trading session at $6.19.
The company reported its EPS on 02/08/2017. Currently, the stock has a 1 Year Price Target of $7.5.
The consensus recommendation, according to Zacks Investment research, is 2. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Strong Sell.
The Stock had a 2 Consensus Analyst Recommendation 30 Days Ago, whereas 60 days ago and 90 days ago the analyst recommendations were 2 and 2 respectively.
Immunomedics Inc. on 02/08/2017 reported its EPS as $-0.23 with the analysts projecting the EPS of the stock as $-0.13. The company beat the analyst EPS Estimate with the difference of $-0.1. This shows a surprise factor of -76.9%.
Many analysts have provided their estimated foresights on Immunomedics Inc. Earnings, with 2 analysts believing the company would generate an Average Estimate of $-0.13.
Whereas they predicted High and Low Earnings Estimate as $-0.11 and $-0.15 respectively. While in the same Quarter Previous year, the Actual EPS was $-0.17.
Analysts are also projecting an Average Revenue Estimate for Immunomedics Inc. as $3.2 Million in the Current Quarter. This estimate is provided by 2 analysts.
The High Revenue estimate is predicted as 5.5 Million, while the Low Revenue Estimate prediction stands at 900 Million. The company’s last year sales total was 899 Million.
For the Current Quarter, the growth estimate for Immunomedics Inc. is 23.5%, while for the Next Quarter the stock growth estimate is 52.9%.
The Company got Downgrade by Wells Fargo on 21-Jun-16 from Outperform to Market Perform.
Insider Trades for Immunomedics Inc. show that the latest trade was made on 1 Dec 2016 where Stark (Donald C), the Director completed a transaction type “Sell” in which 5788 shares were traded at a price of $0.
7 Insider Sales transactions were made totaling 586617 shares traded.
1 analysts projected Price Targets for Immunomedics Inc.. The analysts believe that the company stock price could grow as high as $7.5. The Low Price target projection by analysts is $7.5 and the Mean Price Target is $7.5.
Immunomedics Inc. (IMMU) has the market capitalization of $622.4 Million. The company rocked its 52-Week High of $6.65 on Mar 14, 2017 and touched its 52-Week Low of $1.95 on Jun 27, 2016.
The stock has Return on Assets (ROA) of -129.2 percent. Return on Equity (ROE) stands at 113.9% and Return on Investment (ROI) of -132.9 percent.
The stock is currently showing YTD performance of 68.66 Percent. The company has Beta Value of 1.71 and ATR value of 0.42. The Weekly and Monthly Volatility stands at 7.82% and 7.01%.